Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 25 Jun 2009 |
| Grant of Warrants to Board Members, Management and Employees in Genmab A/S | 18 Jun 2009 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 18 Jun 2009 |
| FDA extends review of ARZERRA(tm) (Ofatumumab) | 16 Jun 2009 |
| Articles of Association of Genmab A/S | 15 Jun 2009 |